Amgen inc(AMGN.US AI Earnings Summary)
AMGN AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
- Against Prior Guidance: Non-GAAP operating margin reached 47%, approximately 1 percentage point above the upper end of the guidance. The median 2026 full-year total revenue guidance provided last quarter was $38.8 billion; this quarter, management raised the full-year total revenue expectation to $38.9 billion–$39.7 billion (median $39.3 billion), indicating higher operational growth momentum than previously expected.
- In One Sentence: AMGEN INC relied on the strong push of its six major growth engines to drive quarterly total revenue past the $10 billion mark and raised its full-year revenue outlook.
Quarterly Highlights
Six major growth engines accelerated simultaneously, delivering strong across-the-board financial performance this quarter.
Six core growth engines grew 27% YoY collectively, accounting for over 70% of revenue: The six drivers—Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, and Biosimilars—together accounted for more than 70% of product sales, with an overall year-over-year increase of 27%. A total of 17 products achieved double-digit growth this quarter, and another 17 products had annualized sales exceeding $1 billion based on quarterly figures, demonstrating portfolio breadth.
Repatha sales grew 37% YoY to $1.1 billion, with US new prescription weekly growth exceeding 60%: The VESALIUS-CV trial established Repatha as the only PCSK9 inhibitor with Phase 3 cardiovascular outcomes data in both primary and secondary prevention. Updated ACC/AHA guidelines support earlier and more aggressive lowering of LDL-C. Management estimates approximately 100 million patients globally have yet to reach their LDL-C targets, with more than 3 million new patients expected to start Repatha this year.
IMDELLTRA (tarlatamab) sales more than doubled YoY to $406 million, with Phase 3 first-line maintenance data shocking the industry: The DeLLphi-305 study showed that IMDELLTRA combined with IMFINZI in first-line maintenance therapy achieved a median overall survival of 21.1 months, compared to only 12.7 months in the control group—a gain of over 8 months. The FDA has shortened the monitoring time for the first two doses from 22-24 hours to 6-8 hours, significantly lowering the barrier for use in community clinics.
UPLIZNA sales grew 191% YoY to $451 million, with strong QoQ momentum in the Generalized Myasthenia Gravis (gMG) indication: UPLIZNA saw strong demand across all approved indications, with a 45% QoQ increase in new and continuing gMG patients. It has launched in 25 markets outside the US. Long-term follow-up data for IgG4-related disease showed that all patients remaining on treatment stayed relapse-free through the first year of the open-label extension.
Pipeline Harvest: Three Phase 3 clinical trials reported positive results in the same quarter: Phase 3 studies for IMDELLTRA in SCLC first-line maintenance, TEZSPIRE in Eosinophilic Esophagitis (EoE), and dazodalibep in systemic Sjögren's disease all met their primary endpoints. Notably, the CROSSING study for TEZSPIRE was the first placebo-controlled trial to prove that a biologic's efficacy in EoE can be sustained through week 52.
Non-GAAP operating margin reached 47%, exceeding the full-year guidance range: While full-year guidance is approximately 45% to 46%, the actual margin this quarter was 47%; Non-GAAP EPS was $6.45, up approximately 14% from $5.64 in the same period last year; free cash flow was $3.7 billion, supporting continuous R&D and capital expenditure.
Biosimilar portfolio grew 26% YoY to $977 million, PAVBLU grew 41% YoY to $300 million: PAVBLU (EYLEA biosimilar) continues to be adopted by retinal specialists benefiting from the convenience of pre-filled syringes. The next wave of biosimilar candidates for EYLEA HD, OPDIVO, KEYTRUDA, and OCREVUS have all entered late-stage clinical development, representing large market opportunities.
Full-year total revenue guidance raised to $38.9B–$39.7B, Non-GAAP EPS raised to $22.90–$23.70: Both metrics were revised upward from the $38.2B–$39.4B and $22.30–$23.50 ranges provided last quarter, reflecting management's increased confidence in full-year execution.